Medicare Advantage Statistics in US 2026 | Best Plans, Costs & Reviews

What is Medicare Advantage?

Medicare Advantage — officially known as Medicare Part C — is a federally regulated private insurance alternative to Original Medicare that combines Part A (hospital) and Part B (medical) coverage, almost always alongside Part D prescription drug coverage, into a single bundled plan. In 2026, these plans are sold by private insurers approved by CMS, and they must cover every benefit that Original Medicare covers — but they can and typically do go further, offering supplemental benefits such as dental, vision, hearing, fitness memberships, over-the-counter item allowances, and in many cases zero monthly premiums beyond the standard Part B premium of $202.90. Every enrollee still pays Part B. What varies enormously from plan to plan — and from county to county — is everything else: the additional premium, the annual out-of-pocket maximum (capped at $9,250 in-network in 2026), the drug formulary, the provider network, and the richness of supplemental benefits. The average enrollee in 2026 can choose from 32 Medicare Advantage plans with drug coverage — a number that sounds generous until you have to compare them all.

What makes Medicare Advantage statistics in 2026 impossible to discuss without nuance is that the program is simultaneously the most enrolled-in Medicare coverage option in US history and the one under the most structural strain it has ever faced. As of February 2026, more than 35 million Americans — over half of all Medicare-eligible beneficiaries — are enrolled in a Medicare Advantage plan. The Congressional Budget Office projects that share reaching 64% by 2034. Yet simultaneously, major insurers are cutting benefits, exiting counties, and posting financial losses. A Johns Hopkins JAMA study confirmed that 1 in 10 enrollees — roughly 2.9 million people — faced forced disenrollment in 2026 when their plan exited their market. Prior authorization denials have surged 56% in recent years, drawing bipartisan Congressional scrutiny. And MedPAC reported to Congress in January 2026 that the program is being overpaid by $76 billion this year relative to what the same beneficiaries would cost in traditional Medicare — a figure now driving a national policy debate over the program’s long-term fiscal architecture. Understanding Medicare Advantage in 2026 means understanding both why 35 million people chose it and what that choice increasingly costs.

Medicare Advantage Statistics 2026 | Key Interesting Facts

  Medicare Advantage 2026: Most Striking Facts at a Glance
  ══════════════════════════════════════════════════════════

  Total Enrollees (Feb 2026, CMS data)
  ████████████████████████████████████████  35+ Million (3.2% YoY growth)

  Share of Eligible Medicare Beneficiaries
  ████████████████████████████████████████  ~55% of eligible beneficiaries

  SNP Enrollment Growth (83% of all MA growth)
  ████████████████████████████████████████  8M+ enrolled in SNPs (+900K YoY)

  Forced Disenrollments in 2026
  ████████████████████████████            2.9 Million (10% of HMO/PPO members)

  MedPAC Estimated Overpayment (2026)
  ████████████████████████████████████████  $76 Billion above traditional Medicare

  Average Monthly Plan Premium (2026, CMS)
  ████                                      $14.00/month (for MA-PDs)

Source: KFF Medicare Advantage Enrollment Grew by About 1 Million (Feb 23, 2026); KFF MA 2026 Spotlight: Plan Offerings (Jan 20, 2026); KFF MA 2026 Premiums & Benefits (Jan 20, 2026); Johns Hopkins Bloomberg / JAMA (Feb 18, 2026); MedPAC January 2026 Status Report; CRFB (Jan 23, 2026); CMS; CoverRight; Kiplinger; Modern Healthcare (Feb 18, 2026)

The interesting facts table above presents a picture of a program at a genuine crossroads — not declining, but no longer on the effortless upward trajectory of its first two decades. The 35 million-plus enrollees and 55%+ market share are historically unprecedented. But the 2.9 million forced disenrollments, the tenfold increase in forced disenrollment rates from the 2018–2024 average, and the 83% of enrollment growth coming from Special Needs Plans rather than general-enrollment plans tell a story of market consolidation under financial stress. The $76 billion MedPAC overpayment estimate for 2026 — $1.2 trillion projected over a decade — is the number that will dominate Medicare policy debates through the rest of the 2020s. It explains why major insurers who were competing aggressively for market share just three years ago are now exiting markets, cutting benefits, and posting losses: the payment model that appeared to generate easy profits was built on a foundation of upcoding and favorable selection that CMS is methodically unwinding through the new V28 risk adjustment model.

The average monthly premium of $14.00 remains extremely attractive compared to Medigap alternatives — and 67% of MA-PD plans still charge nothing beyond the standard Part B premium. That price signal continues to draw beneficiaries in, particularly those who are healthy and value the supplemental benefits. But the $9,250 maximum in-network out-of-pocket cap, the near-universal prior authorization requirements affecting 99% of enrollees, and the quiet erosion of supplemental benefits — OTC allowances available in only 66% of plans in 2026, down from 75% previously — mean that the gap between the promise at enrollment and the reality at the point of care is wider than it has been in years. For the 1 in 3 MA enrollees now in a plan rated below 4 stars by CMS, the quality data compounds the financial picture.

Medicare Advantage Statistics 2026 | Best Plans — Top Carriers Rated by Stars & Benefits

  Top Medicare Advantage Carriers 2026 — Star Ratings & Enrollment
  ══════════════════════════════════════════════════════════════════

  UnitedHealthcare   Avg 4.2 stars   9.4M enrollees   All 50 states
  ████████████████████████████████████████████████████████████████████

  Humana             Avg 4.1 stars   7M+ enrollees    82% of counties
  ████████████████████████████████████████████████████████████

  Kaiser Permanente  Highest ratings  Selective         8 states only
  ████████████████████████████████████████████████████████████████████

  Aetna/CVS          Moderate         29K enrollee loss 2026
  ████████████████████████████████████████████████

  Elevance Health    Declining        -368K enrollees  2026
  ████████████████████████████████████

  Average Market Star Rating (2026, CMS)
  3.66 ██████████████████████████████████████  (up from 3.65 in 2025)

  Only 2% of MA members in 5-star plans (2026)
  ██  (vs 8% in 2024 — sharp quality decline)

Source: CMS 2026 Star Ratings Fact Sheet; HealthScape Advisors Feb 2026 Enrollment Report; KFF MA 2026 Spotlight: Premiums & Benefits; Healthcare Finance News Star Ratings list; SeniorSimple.org Best MA Plans 2026 (Apr 28, 2026); STAT News (Apr 2, 2026); KFF Feb 2026 enrollment data

The best Medicare Advantage plans in 2026 share a common quality signature: high CMS star ratings, broad network access, and reliable supplemental benefits that hold value year-over-year rather than being cut mid-cycle. UnitedHealthcare holds the largest enrollment footprint — 9.4 million members in all 50 states — and its 4.2-star average rating with 78% of members in 4-star or higher plans reflects the quality infrastructure that comes with scale. The AARP co-branding and 1.4 million+ in-network providers make it the broadest-access national choice for beneficiaries who travel, have multiple specialists, or live in areas with fragmented healthcare networks. Humana’s extraordinary enrollment surge of 1.2 million new members in 2026 positions it to potentially overtake UHC as the largest MA insurer — and its best plans offer genuinely generous supplemental benefits, including the $250 quarterly OTC allowance and comprehensive dental. The caveat is that Humana’s largest single contract (H5216) remains below 4 stars, and the company’s rapid expansion is drawing analyst scrutiny about whether its margins can sustain it.

Kaiser Permanente consistently earns the highest star ratings among any major carrier but operates only in 8 states and DC — making it unavailable to most beneficiaries. For the approximately one-third of enrollees whose plans sit below 4 stars in 2026, the quality deficit translates into measurable care experience gaps: fewer covered preventive services, higher administrative friction, and reduced access to quality bonuses that fund supplemental benefits. The CMS decision to eliminate 11 grading measures and revise cut-points in the 2026 star ratings — a change analysis firms estimated gives plans an $18.6 billion windfall — has drawn criticism from patient advocates who argue it rewards financial engineering rather than care improvement. For beneficiaries choosing a plan, the practical advice from every independent Medicare expert in 2026 is consistent: look beyond the monthly premium, verify that your specific doctors and drugs are covered, and check the star rating directly on Medicare.gov before enrolling.

Medicare Advantage Statistics 2026 | Costs, Out-of-Pocket Maximums & Premium Trends

  Medicare Advantage 2026 Premium & Cost Structure
  ══════════════════════════════════════════════════

  Average monthly MA-PD premium (CMS, 2026):     $14.00   ████
  (Includes $0-premium plans in the average)

  Part B premium (paid by ALL MA enrollees):    $202.90  ████████████████████████████████

  Maximum in-network OOP cap (2026):             $9,250  ████████████████████████████████████████
  Average MOOP increase for 35% of enrollees:     +$981  ████████████████████████████████

  Drug Deductible (enrollment-weighted avg):       $417   ████████████████
  (Up 35% from $308 in 2025)

  $0 drug deductible enrollment share:
  2024:  60%  ████████████████████████████████████████████████████████████
  2025:  31%  ████████████████████████████████
  2026:  14%  ██████████████  ← Sharp erosion

Source: CMS 2026 Rate Announcement; KFF MA 2026 Spotlight: Premiums & Benefits (Jan 20, 2026); CoverRight 2026 AEP Analysis; Milliman MACVAT 2026 State of MA Industry (Mar 10, 2026); JEC / The Hill (Mar 10, 2026); AARP / Medicare Rights Center (Mar 2026); Kiplinger (2026)

The cost statistics for Medicare Advantage in 2026 reveal a widening gap between the headline premium number and the total financial exposure enrollees actually face. The $14.00 average monthly premium is technically accurate — but it includes the 67% of plans that charge zero in its calculation, masking the fact that the 33% of plans with real premiums are becoming more expensive. More critically for beneficiaries, the drug deductible erosion is a hidden and largely unreported cost shift. Moving from 60% of enrollees with $0 drug deductibles in 2024 to just 14% by 2026 represents a structural transfer of drug cost risk back to beneficiaries — particularly damaging for enrollees with multiple chronic conditions who fill many prescriptions early in the year before meeting their deductible. The 35% increase in the average drug deductible from $308 to $417 in a single year is the kind of change that significantly alters the real-world affordability of coverage for the sickest MA enrollees.

The Milliman MACVAT data quantifying a $7 PMPM decline in non-Medicare supplemental benefit value in 2026 — the largest single-year erosion ever recorded in the dataset — confirms that the “free extras” that drove MA enrollment growth are being systematically rolled back. OTC allowances, dental coverage richness, fitness memberships, and transportation benefits are all contracting. Meanwhile, the revelation from the bipartisan Senate Joint Economic Committee that MA overpayments caused Part B premiums to rise from $185 to $203 per month in a single year — and have added $82 billion to cumulative Part B premiums since 2016 — means that every Medicare beneficiary, including the 13.5 million in Original Medicare, is paying higher premiums because of the MA overpayment structure. For policymakers, healthcare economists, and informed beneficiaries, this is the data point that most clearly illustrates why the “free plan” narrative about Medicare Advantage requires more careful scrutiny in 2026.

Medicare Advantage Statistics 2026 | Enrollment by Insurer, State & Special Needs Plans

  Medicare Advantage Market Share — Top 5 Insurers (Feb 2026)
  ════════════════════════════════════════════════════════════

  UnitedHealthcare   9.4M   ████████████████████████████████████████████████████████
  Humana             7.0M+  ████████████████████████████████████████████████
  CVS/Aetna          ~5M    ████████████████████████████████████
  Elevance Health    ~3.5M  ████████████████████████████
  Kaiser Permanente  ~1M    ████████

  SNP Enrollment Composition (8M+ total in 2026):
  D-SNPs (dual Medicare/Medicaid)   78%  ████████████████████████████████████████
  C-SNPs (chronic conditions)        ~15% █████████████
  I-SNPs (institutional)               7% ███

  State with highest MA penetration:  Florida (among top 3 nationally)
  State with only ONE insurer left:    Vermont (Blue Cross exited 2026)

Source: KFF Medicare Advantage Enrollment Grew by ~1 Million (Feb 23, 2026); KFF MA 2026 Spotlight: Plan Offerings (Jan 20, 2026); HealthScape Advisors MA 2026 Enrollment Report (Feb 26, 2026); Johns Hopkins Bloomberg / JAMA (Feb 18, 2026); RISE Health (Feb 24, 2026); Healthcare Dive; CMS 2026 landscape files

The carrier-level and geographic enrollment statistics for Medicare Advantage in 2026 reveal a market in the early stages of a structural consolidation not seen since the program’s rapid expansion era. The combined trajectory of UnitedHealthcare losing 530,000+ members while Humana gains 1.2 million represents the largest single-cycle market share shift in the program’s modern history. UHC’s deliberate pullback from 225 counties reflects a strategic prioritization of margin over enrollment — a reversal of the growth-at-any-cost posture that characterized the industry from 2015 to 2023. The emergence of startups like Alignment, Devoted, and Clover as net beneficiaries of the incumbent retreats signals a potential structural opening for more focused, regionally concentrated plans to serve the beneficiaries major national carriers have abandoned.

The SNP growth story is arguably the most consequential structural development in the Medicare Advantage market in 2026. With SNPs accounting for 83% of all enrollment growth, the doubling of D-SNP plans since 2020 (540 to 1,019), and the more than 70% single-year surge in C-SNP enrollment, Special Needs Plans have shifted from a niche segment to the primary growth engine of the entire program. This matters because SNP enrollees — dual-eligibles and people with serious chronic conditions — are precisely the population whose healthcare needs are most complex and most dependent on stable, high-quality plan relationships. The fact that D-SNPs alone account for 78% of all SNP enrollment means millions of the country’s most vulnerable Medicare beneficiaries are increasingly concentrated in a segment that is experiencing the fastest growth and the least regulatory scrutiny. For policymakers, this concentration is both an opportunity to improve care coordination and a fiscal risk that MedPAC has flagged repeatedly.

Medicare Advantage Statistics 2026 | Prior Authorization, Coverage Denials & Federal Oversight

  Medicare Advantage Prior Authorization — 2024 Data (Most Recent Full-Year)
  ══════════════════════════════════════════════════════════════════════════

  Total prior auth requests in 2024:   52.9 Million  ████████████████████████████████████████
  Prior auth requests in 2023:         49.8 Million  ████████████████████████████████████
  Denial rate — UnitedHealthcare:      12.8%         ████████████████████████████████████████
  Denial rate — Humana:                 5.8%         ██████████████████████

  2026 New Rules: Urgent requests must be answered within 72 hours
                  Standard requests: within 7 days
                  Approved services: cannot be retrospectively denied (except fraud)

  MA Federal Overpayment (2026, MedPAC):
  Upcoding contribution:    ~$41B  ████████████████████████████████████████
  Favorable selection:      ~$35B  ███████████████████████████████████
  Total overpayment:        $76B   ████████████████████████████████████████████████████████████████████████████████

Source: KFF Medicare Advantage Insurers Made Nearly 53 Million Prior Auth Determinations in 2024 (Jan 28, 2026); MedPAC Jan 2026 Status Report; CRFB Jan 2026; JEC Congressional Report / The Hill (Mar 10, 2026); AARP (Mar 2026); Medicare Rights Center (Mar 12, 2026); SavingAdvice.com / CMS Apr 2026; AHCANCAL 2026 MA Overview

The prior authorization and federal oversight statistics for Medicare Advantage in 2026 represent the most politically charged dimension of the program’s data landscape. The jump from 49.8 million to nearly 53 million prior authorization requests in a single year — driven purely by enrollment growth, not changes in individual utilization — means the administrative burden on physicians and patients scales with every new MA enrollee. The 99% of MA members who face prior authorization requirements are not a marginal group; they are the entirety of the program. And the 56% surge in denial rates combined with the federal finding that some denials involved care that legally met Medicare coverage standards transforms a utilization management debate into a patient rights issue. The 2026 CMS rules requiring 72-hour response to urgent requests and prohibiting retroactive reversal of approved services are meaningful reforms — but they address the edges of a system whose fundamental architecture incentivizes restriction.

The $76 billion overpayment estimate from MedPAC is the number that most fundamentally challenges the popular narrative about Medicare Advantage as a cost-efficient private-sector alternative to traditional Medicare. When independent analysts at the Committee for a Responsible Federal Budget project $1.2 trillion in cumulative overpayments through 2035 — of which $520 billion comes from the Medicare Hospital Insurance trust fund (nearly the size of the entire projected HI deficit) — the fiscal implications for the broader Medicare program become unavoidable. The fact that Original Medicare beneficiaries, who receive none of MA’s supplemental benefits, bore $6 billion of the 2025 premium burden created by MA overpayments makes this not just a policy abstraction but a direct financial harm to the 13.5 million Medigap holders and other traditional Medicare enrollees who chose a different coverage path. How Congress responds to MedPAC’s recommendations in 2026 and 2027 will determine whether Medicare Advantage continues its march toward 64% enrollment by 2034 or enters a structural correction.

Disclaimer: This research report is compiled from publicly available sources. While reasonable efforts have been made to ensure accuracy, no representation or warranty, express or implied, is given as to the completeness or reliability of the information. We accept no liability for any errors, omissions, losses, or damages of any kind arising from the use of this report.

Email ID:

Please enable JavaScript in your browser to complete this form.

Email

Email *

SUBSCRIBE